First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV

Inclusion Criteria

• Adult males or females aged ≥18 to ≤65 years at screening (according to country/local regulations)
• BMI ≤32kg/m2
• Able to provide informed consent indicating they understand the purpose of, and procedures required, for the study and are willing to participate
• If female, willing not to become pregnant up to 8 weeks after last dose of study vaccine and up to 5 months after the last dose of nivolumab
• If female: Not pregnant or breast feeding and one of the following:
• Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are post menopausal, as defined by no menses in ≥1 year and without an alternative medical cause)
• Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to study vaccine and 8 weeks after study vaccine and 5 months after the last dose of nivolumab. Highly effective methods of contraception include one or more of the following:

(i) Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant

(ii) Combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation:

• oral
• intravaginal
• transdermal

(iii) Progestogen-only hormonal contraception associated with inhibition of ovulation:

• oral
• injectable
• implantable

(iv) An intrauterine device

(v) Bilateral tubal occlusion

• Documented evidence of chronic HBV infection (e.g. HBsAg positive ≥6 months with detectable HBsAg levels at screening)
• Receipt of only either entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or besifovir for at least 12 months before screening
• Virally suppressed (HBV-DNA viral load 9 kilopascals (kPa) (or the equivalent) within ≤ 6 months of screening, OR
• Screening FibroTest >0.48 and aspartate aminotransferase (AST) to platelet ratio index (APRI) of >1.
• ALT >3 x upper limit of normal (ULN), international normalized ratio (INR) >1.5 unless the participant was stable on an anticoagulant regimen affecting INR, albumin 1.5 x ULN, platelet count 10 mg/day) or biologics (e.g. monoclonal antibodies, IFN) within 3 months of screening
• Receipt of immunoglobulin or other blood products within 3 months prior to enrolment
• Receipt of any investigational drug or vaccine within 3 months prior to screening
• Receipt of any adenoviral-based vaccine within 3 months prior to administration of ChAdOx1-HBV on Day 0, or plan to receive an adenoviral-based vaccine within 3 months after Day 0
• Receipt of any live vaccines within 30 days prior to screening
• Receipt of any inactivated vaccines within 14 days prior to screening,
• History of severe hypersensitivity or anaphylactic reactions likely to be exacerbated by any component of the vaccine or nivolumab
• Malignancy within 5 years prior to screening with the exception of specific cancers that are cured by surgical resection (e.g. except basal cell skin carcinoma of the skin and cervical carcinoma). Participants under evaluation for possible malignancy are not eligible
• Current alcohol or substance abuse judged by the Investigator to potentially interfere with participant safety and compliance
• Significant cardiac disease or unstable uncontrolled cardiac disease
• Any laboratory test which is abnormal, and which is deemed by the Investigator to be clinically significant
• Cytotoxic agents, other anti HBV or traditional herbal medicines which, in the opinion of the Investigator, may have activity against HBV within the previous 6 months prior to randomization
• Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study